5+ Leading Her2+ Non-Small Cell Lung Cancer Pipeline Companies are working to improve the Treatment Landscape

February 08 20:54 2023
5+ Leading Her2+ Non-Small Cell Lung Cancer Pipeline Companies are working to improve the Treatment Landscape

DelveInsight’s, “HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight, 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including HER2-mutant Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive HER2-mutant Non-Small Cell Lung Cancer pipeline products in this space.

 

In the HER2-mutant Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, HER2-mutant Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, HER2-mutant Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

 

  • Over 5+ HER2-mutant Non-Small Cell Lung Cancer companies are evaluating 5+ HER2-mutant Non-Small Cell Lung Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the HER2-mutant Non-Small Cell Lung Cancer market would significantly increase market revenue.

 

  • The leading HER2-mutant Non-Small Cell Lung Cancer Companies includes Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals, Inc., and others.

 

  • Promising HER2-mutant Non-Small Cell Lung Cancer pipeline therapies includes neratinib, temsirolimus, Trastuzumab deruxtecan, Abemaciclib, Pembrolizumab, Anastrozole, TAK-788, RC48, XMT-1522, Poziotinib, and others.

 

  • The HER2-mutant Non-Small Cell Lung Cancer Companies and academics are working to assess challenges and seek opportunities that could influence HER2-mutant Non-Small Cell Lung Cancer R&D. The HER2-mutant Non-Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve HER2-mutant Non-Small Cell Lung Cancer.

 

To explore more information on the latest breakthroughs in the Her2+ Non Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ Her2+ Non Small Cell Lung Cancer Pipeline Outlook

 

Her2+ Non Small Cell Lung Cancer Overview

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. NSCLC is one of the most genomically diverse cancers, making it very difficult to treat. For all NSCLC patients who have the adenocarcinoma subtype, testing for alterations in epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (MET), b-raf proto-oncogene (BRAF), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), ret proto-oncogene (RET) and neurotrophic tyrosine receptor kinase (NTRK) is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines. Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a distinct molecular subtype.

 

Latest Breakthroughs/News for HER2+ Non Small Cell Lung Cancer Treatment Landscape

  • The U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who are unresectable locally advanced or metastatic and have received at least two additional systemic therapies in the metastatic stage. The approval is based on data from the Phase 3 TROPiCS-02 research on progression-free survival and overall survival that are statistically significant and clinically meaningful. As stated in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network® (NCCN®), trodelvy is now also indicated as a Category 1, preferred treatment for metastatic HR+/HER2- breast cancer.
  • Despite decades of progress, patients with HR+/HER2-metastatic breast cancer who have already received treatment still require additional treatment alternatives. As the principal investigator of the TROPiCS-02 study, Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the UCSF Helen Diller Family Comprehensive Cancer Center, United States, said, “Nearly all patients with this type of breast cancer will eventually develop resistance to endocrine-based therapies and progress on available chemotherapies.” “This approval is important for the community fighting breast cancer. After endocrine-based therapy and chemotherapy, we had few treatment alternatives for patients, therefore it is extraordinary to observe a clinically significant survival advantage of more than three months with an improvement in quality of life.

 

For further information, refer to the detailed Her2+ Non-Small Cell Lung Cancer Unmet Needs, Her2+ Non-Small Cell Lung Cancer Market Drivers, and Her2+ Non-Small Cell Lung Cancer Market Barriers, click here for Her2+ Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

HER2+ Non Small Cell Lung Cancer Emerging Drugs Profile 

  • DZD-9008: Dizal Pharmaceuticals

DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFRexon20 insertion mutation-positive NSCLC and HER2-mutated NSCLC. In the open-label, multicenter phase I/II study (NCT03974022), 220 patients with EGFRexon20 insertion mutation-positive or HER2-positive NSCLC were treated with DZD9008 at doses of 50 mg to 400 mg once daily.

  • Enhertu: AstraZeneca

Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial. Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastro esophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

  • Pyrotinib:  Jiangsu Hengrui Medicine

Pyrotinib is a novel irreversible and selective EGFR/HER2 tyrosine kinase inhibitor developed by Hengrui. In 2018, pyrotinib was approved in China in combination with capecitabine for the treatment of relapsed or metastatic HER2-positive breast cancer. Currently, two Phase III studies are ongoing to evaluate pyrotinib as 1st-line treatment (NCT03863223) and extended adjuvant treatment (NCT03980054), respectively in HER2-positive breast cancer patients. In addition to breast cancer, pyrotinib demonstrated superior clinical benefits in advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 mutation in a Phase II study. A global Phase III study (NCT04447118) is ongoing to investigate pyrotinib in patients with advanced non-squamous NSCLC with HER2 exon 20 mutation who previously failed platinum-based chemotherapy.

 

HER2+ Non Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for HER2-mutant Non-Small Cell Lung Cancer. The companies which have their HER2-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Preregistration include, AstraZeneca.

 

Request a sample and discover the recent advances in Her2+ Non Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Her2+ Non Small Cell Lung Cancer Treatment Landscape

 

Scope of the Her2+ Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • HER2-mutant Non-Small Cell Lung Cancer Companies- Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals, Inc., and others.
  • HER2-mutant Non-Small Cell Lung Cancer pipeline therapies- Neratinib, temsirolimus, Trastuzumab deruxtecan, Abemaciclib, Pembrolizumab, Anastrozole, TAK-788, RC48, XMT-1522, Poziotinib, and others.
  • HER2-mutant Non-Small Cell Lung Cancer Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

 

Dive deep into rich insights for drugs for HER2-mutant Non-Small Cell Lung Cancer Market Drivers and HER2-mutant Non-Small Cell Lung Cancer Market Barriers, click here @ HER2-mutant Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. HER2-mutant Non-Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2-mutant Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Enhertu: AstraZeneca
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. DZD-9008: Dizal Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HER2-mutant Non-Small Cell Lung Cancer Key Companies
  21. HER2-mutant Non-Small Cell Lung Cancer Key Products
  22. HER2-mutant Non-Small Cell Lung Cancer- Unmet Needs
  23. HER2-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
  24. HER2-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
  25. HER2-mutant Non-Small Cell Lung Cancer Analyst Views
  26. HER2-mutant Non-Small Cell Lung Cancer Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Her2+ Non Small Cell Lung Cancer Mergers and acquisitions, Her2+ Non Small Cell Lung Cancer Licensing Activities @ Her2+ Non Small Cell Lung Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

view more articles

About Article Author